Verification evidence is still being completed.
PDF / print export
AlgiPharma AS
Sandvika, Norway
- Verified lead
- Yngvar P. Berg
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Alginate Oligomer Therapeutics, Cystic Fibrosis, Biofilm Disruption, and Antimicrobial Resistance
- Review cycle
- 24 April 2026
- Full address
- Industriveien 33, N-1337 Sandvika, Norway
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- AlgiPharma team page listing Yngvar P. Berg as Chief Executive Officer.
- Editorial note
- Sandvika alginate-chemistry biotech with named CEO, Phase 2b cystic-fibrosis program, and documented public-funding support from the CFF, Horizon 2020, and Norwegian Research Council.
Alginate Oligomer Therapeutics, Cystic Fibrosis, Biofilm Disruption, and Antimicrobial Resistance
Public CEO disclosure on company site, CFF award documentation, Horizon 2020 and NRC support
Sandvika alginate-chemistry biotech with named CEO, Phase 2b cystic-fibrosis program, and documented public-funding support from the CFF, Horizon 2020, and Norwegian Research Council.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Sandvika, Norway
AlgiPharma AS
Alginate Oligomer Therapeutics, Cystic Fibrosis, Biofilm Disruption, and Antimicrobial Resistance · Clinical-stage alginate oligomer development
Sandvika alginate-chemistry biotech with named CEO, Phase 2b cystic-fibrosis program, and documented public-funding support from the CFF, Horizon 2020, and Norwegian Research Council.
- Lead
- Yngvar P. Berg (verified ↗)
- Address
- Industriveien 33, N-1337 Sandvika, Norway (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical-stage alginate oligomer development
- Capabilities
- Alginate Oligomer Chemistry · OligoG CF-5/20 Phase 2b Cystic-Fibrosis Program · Biofilm and Antimicrobial-Resistance Research
- Founded
- 2004
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Yngvar P. Berg
Chief Executive Officer
Full addressIndustriveien 33, N-1337 Sandvika, Norway
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Clinical-stage alginate oligomer development
Sandvika, Norway. Alginate Oligomer Therapeutics, Cystic Fibrosis, Biofilm Disruption, and Antimicrobial Resistance. Review completed on 24 Apr 2026.
Norwegian Medicines Agency and EMA for clinical-program oversight
Public CEO disclosure on company site, CFF award documentation, Horizon 2020 and NRC support
Alginate Oligomer Therapeutics, Cystic Fibrosis, Biofilm Disruption, and Antimicrobial Resistance
Sandvika alginate-chemistry biotech with named CEO, Phase 2b cystic-fibrosis program, and documented public-funding support from the CFF, Horizon 2020, and Norwegian Research Council.
Editorial note
AlgiPharma combines documented public-funding support from the Cystic Fibrosis Foundation, Horizon 2020, and the Norwegian Research Council with a named CEO and a Phase 2b cystic-fibrosis program on OligoG.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Alginate Oligomer Chemistry
OligoG CF-5/20 Phase 2b Cystic-Fibrosis Program
Biofilm and Antimicrobial-Resistance Research
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Alginate oligomer chemistry
Clinical trial operations
Partner GMP manufacturing
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is AlgiPharma AS located?
- AlgiPharma AS operates from Industriveien 33, N-1337 Sandvika, Norway, Sandvika, Norway.
- Who runs AlgiPharma AS?
- AlgiPharma AS is led by Yngvar P. Berg, Chief Executive Officer. Verified 24 Apr 2026.
- What does AlgiPharma AS do?
- Sandvika alginate-chemistry biotech with named CEO, Phase 2b cystic-fibrosis program, and documented public-funding support from the CFF, Horizon 2020, and Norwegian Research Council. Core capabilities: Alginate Oligomer Chemistry, OligoG CF-5/20 Phase 2b Cystic-Fibrosis Program, Biofilm and Antimicrobial-Resistance Research.
Editorial context
Related technical briefs
Briefs that name Sandvika as a covered market or city.
European Cardiometabolic Therapeutics 2026: Diabetes, Heart Failure, Fibrosis, RenalEuropean Rare Disease & Orphan Therapeutics 2026: Sobi, Hansa, Ascendis, Calliditas, and the Orphan ClusterEuropean Microbiome & Live Biotherapeutics 2026: Live-Biotherapeutic Products, Microbial CDMO, Industrial Microbiome